Clinical study reinforces gastrointestinal benefits of probiotic BB-12

Results from one of the world’s largest clinical studies on probiotics show that the probiotic strain named BB-12 can be part of the solution by improving bowel regularity.

The study, initiated by Chr. Hansen in 2011, included more than 1200 subjects in France, the UK and Germany; all healthy but experiencing low defecation frequency and abdominal discomfort. The study has produced the largest dataset ever published from a randomised, placebo-controlled study on the effect of probiotics on bowel function.

Results from the study show that the odds for having more regular bowel movements were significantly higher when consuming the BB-12 probiotic strain for four weeks compared to the placebo group, demonstrating that BB012 had a clinically relevant effect on bowel regularity.

Mikkel Jungersen, Scientific Advisor, Human Health & Nutrition, Chr. Hansen, said, “Once again, it is confirmed that the BB-12 probiotic strain can bring significant gastrointestinal benefits to those who experience digestive issues. What is truly unique about this study is its size of more than 1200 subjects varying in age from 18 to 70, which has resulted in the largest dataset available on the effect of probiotics on bowel function.”

BB-12 the “best documented Bifidobacterium in the world”

The BB-12 probiotic strain originates from Chr. Hansen’s culture collection and has been used as an ingredient in food and dietary supplements since 1985. Over the last 30 years, more than 170 clinical studies have shown that this probiotic strain has a positive effect on the immune and gastrointestinal system. Today, it is consumed by hundreds of millions of people all over the world every day.

Mikkel Jungersen continued, “We are committed to delivering the best documented probiotics and the BB-12 probiotic strain is the best documented Bifidobacterium in the world. With these new results, it now truly stands out as a strong probiotics within bowel function.”